TScan Therapeutics (TCRX) FCF Margin (2020 - 2026)
TScan Therapeutics' (TCRX) quarterly FCF Margin came in at 2479.53% in Q1 2026, down 67769.0% year-on-year from N/an in Q1 2025, and down 99.17% on a QoQ basis from 1244.92% in Q4 2025.
TScan Therapeutics (TCRX) FCF Margin (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has 7 years of FCF Margin data on file, last reported at 2479.53% in Q1 2026.
- On a quarterly basis, FCF Margin fell 67769.0% year-over-year to 2479.53% in Q1 2026; TTM through Mar 2026 was 1319.58%, a 148053.0% increase from a year earlier, with the FY2025 full-year figure at 1310.66%, up 276061.0% from the prior year.
- FCF Margin for Q1 2026 stood at 2479.53%, down from 1244.92% in the prior quarter.
- Over the last five years, FCF Margin for TCRX reached as high as 199.67% in Q3 2023 and fell as low as 5295.41% in Q1 2024.
- Historically, FCF Margin has averaged 1676.72% across 5 years, with a median of 1061.87% in 2025.
- Across the five-year window, FCF Margin plunged 488832 bps in 2024 and jumped 399168 bps in 2025, its largest moves.
- Year by year, FCF Margin stood at 513.15% in 2022, then surged by 36 bps to 329.0% in 2023, then sank by 1194 bps to 4255.64% in 2024, then surged by 71 bps to 1244.92% in 2025, then slumped by 99 bps to 2479.53% in 2026.
- Per Business Quant data, the three most recent FCF Margin figures were 2479.53% in Q1 2026, 1244.92% in Q4 2025, and 1257.98% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 10.45% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | TScan Therapeutics | 100.59 Mn | -27.47 Mn | - | -2,479.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,479.53% |
| Dec 31, 2025 | -1,244.92% |
| Sep 30, 2025 | -1,257.98% |
| Jun 30, 2025 | -1,061.87% |
| Mar 31, 2025 | -1,801.84% |
| Dec 31, 2024 | -4,255.64% |
| Sep 30, 2024 | -2,791.99% |
| Jun 30, 2024 | -5,053.54% |
| Mar 31, 2024 | -5,295.41% |
| Dec 31, 2023 | -329.00% |
| Sep 30, 2023 | 199.67% |
| Jun 30, 2023 | -701.56% |
| Mar 31, 2023 | -407.09% |
| Dec 31, 2022 | -513.15% |
| Sep 30, 2022 | -450.49% |
| Jun 30, 2022 | -376.23% |
| Mar 31, 2022 | -683.71% |
| Dec 31, 2021 | -581.32% |
| Sep 30, 2021 | -870.27% |
| Jun 30, 2021 | -324.51% |